Day D, Lubowski T J, Yamaga C C, Main J, Van Vleet J, Ambegaonkar A
Pfizer Pharmaceuticals Group, Pfizer Inc, New York, New York 10017, USA.
Clin Ther. 1999 Aug;21(8):1418-25. doi: 10.1016/s0149-2918(99)80042-3.
Evaluation of the cost-effectiveness of antibiotic regimens has become an essential part of drug selection for pharmacists and physicians. However, these evaluations can be complicated, time-consuming, and, if the data used are not based on local conditions, misleading. The computer program Dare to Compare 98 was developed to provide an analysis of empiric antibiotic regimens. The Infectious Disease Challenge portion of the program lists the commonly identified pathogens in specific infectious diseases. The Antibiogram Susceptibility Reports section generates susceptibility reports based on local antibiogram data or data from institutions nationwide that have similar demographic profiles. Susceptibility information is combined with cost data in the Quality/Cost Index section. Comparison of the quality and cost index values allows the user to determine which regimens provide the optimal microbiologic activity and cost values for treatment of a particular infectious disease based on local data. Thus Dare to Compare 98 can help pharmacists and physicians evaluate antibiotic regimens and their suitability for inclusion in formularies and disease-management algorithms.
抗生素治疗方案的成本效益评估已成为药剂师和医生选择药物的重要组成部分。然而,这些评估可能很复杂、耗时,而且,如果所使用的数据并非基于当地情况,可能会产生误导。开发计算机程序“敢于比较98”是为了对经验性抗生素治疗方案进行分析。该程序的“传染病挑战”部分列出了特定传染病中常见的病原体。“药敏报告”部分根据当地药敏数据或来自全国具有相似人口统计学特征机构的数据生成药敏报告。药敏信息在“质量/成本指数”部分与成本数据相结合。通过比较质量和成本指数值,用户可以根据当地数据确定哪些治疗方案为治疗特定传染病提供了最佳的微生物活性和成本价值。因此,“敢于比较98”可以帮助药剂师和医生评估抗生素治疗方案及其是否适合纳入处方集和疾病管理算法。